Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin's lymphoma that affects the T-cells in the immune system and appears on the skin as lesions, tumors, or plaques. About 20,000 people in the U.S. are believed to have CTCL, with similar numbers in Europe and significant cases in Asia. The majority of patients with CTCL have early-stage disease (called Mycosis Fungoides), which, with careful disease management, may never progress to later stages of disease. However, there is NO FDA-approved first-line therapy for early-stage CTCL.
The company we are profiling today is Soligenix Inc. (SNGX), which is developing a safer, more convenient alternative to commonly used approaches for early-stage CTCL.
For comments and feedback: editorial@rttnews.com